Slide 1: 2013 First nine months results
2013 First nine months results 30 OCTOBER 2013
Slide 2: First nine months 2013 highlights
First nine months 2013 highlights • Revenue € 702.0 million, up 13.2%. • EBITDA € 174.0 million or 24.8% of sales, up 15.4% • Operating income (EBIT) € 148.3 million or 21.1% of sales, up 12.0% • Net income € 101.5 million or 14.5% of sales, up 9.0% • Successful conclusion of the acquisition of a po
Slide 3: Composition of revenue
Composition of revenue New markets and new products drive growth (million Euro) Jan-Sep 2013 Jan-Sep 2012 Change % Italy 168.6 162.7 3.6 France 85.0 89.8 (5.4) Russia and other CIS countries 66.6 36.2 83.7 Germany 58.1 51.4 13.0 Turkey 49.7 48.1 3.5 U.S.A. 40.2 5.3 n.s. Portugal 23.7 24.9 (4.8) Spai
Slide 4: A growing presence in Eastern Europe, Russia and the U.S.A.
A growing presence in Eastern Europe, Russia and the U.S.A. Russia and other CIS 9.8% Germany 8.6% France 12.5% Turkey 7.3% USA 5.9% Portugal 3.5% Italy 24.9% Spain 3.5% Other W. Europe countries 2.7% Other CEE 3.7% Other international sales 17.6% (sales to licensees and exports) Data: First nine mo
Slide 5: Main product sales
Main product sales Corporate products including orphan drugs now account for 46.5% of revenue (million Euro) Jan-Sep 2013 Jan-Sep 2012 Change % Zanidip® (lercanidipine) 86.2 91.4 (5.7) Zanipress® (lercanidipine+enalapril) 42.9 36.5 17.3 Urorec® (silodosin) 34.1 22.9 48.6 Livazo® (pitavastatin) 16.8
Slide 6: A richer product portfolio
A richer product portfolio Orphan drugs 13.9% Other corporate products 5.7% OTC 15.4% Livazo 2.4% Urorec 4.9% Zanipress 6.1% Zanidip 12.3% Subsidiaries’ local product portfolios 35.1% Pharmaceutical chemicals 3.4% Other revenue 0.8% Data: First nine months 2013 Total revenue € 702.0 m 6
Slide 7: First nine months 2013 results
First nine months 2013 results Significant sales and earnings growth (million Euro) Jan-Sep 2013 Jan-Sep 2012 Change % Revenue 702.0 620.3 13.2 Gross Profit 460.1 401.6 14.6 as % of revenue 65.5 64.7 SG&A Expenses 244.9 221.2 10.7 as % of revenue 34.8 35.7 R&D Expenses 55.4 44.5 24.6 as % of revenue
Slide 8: Financial position and Shareholders' equity
Financial position and Shareholders’ equity (million Euro) 30 Sep 2013 31 Dec 2012 Change Cash and short-term financial 115.6 38.4 77.2 investments Bank overdrafts and short-term loans (16.5) (56.0) 39.5 Loans – due within one year (8.0) (8.1) 0.1 Loans – due after one year (224.4) (127.7) (96.7) NE
Slide 9: Financial projections 2013 targets
Financial projections 2013 targets 2012 2013 (million Euro) Actual Targets Revenue 828.3 > 930 Operating income 167.0 > 190 (EBIT) Net Income 118.5 > 132 9
Slide 10: Company declarations, disclaimers and profile
Company declarations, disclaimers and profile DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY’S FINANCIAL REPORTS The manager responsible for preparing the company’s financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finan